Gencyst is Finland based biotech, nurturing a fast-developing pharma industry, providing services for bioavailability (BA) & bioequivalence (BE) studies, therapeutic equivalence, and phase-I clinical trials. Gencyst Clinical Center (GCC) is offering advance and fully automated bioequivalence analysis of generic (biosimilar) and new drugs, give an expert assessment of their effectiveness and safety before launching into mass production.
The GCC is equipped with fully automated modern equipment, including mobile systems for monitoring the condition of participants (volunteers), has necessary operational licenses and quality assurance certificates.
GCC has participated in bioequivalence and pharmacokinetic studies. We are expert in detecting low molecular weight compounds in biological samples with high precision.